186rnl

Phase 1

NNYU Langone Health

186rnl is one of 20 therapeutic programs targeting Leptomeningeal Metastases. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Leptomeningeal MetastasesNot yet recruiting

Leptomeningeal MetastasisCompleted

Leptomeningeal MetastasesPhase 1

Not yet recruiting

Leptomeningeal MetastasisPhase 1

Completed

Competition

Competitive Landscape

18 competitors in Leptomeningeal Metastasis

#DrugCompanyPhaseTrials

Cytosar

Trexall

Lenvima

Alimta

10 5

Tepadina

Jazz Pharmaceuticals

Phase 2

1 6

Intrathecal Chemotherapy

PPrincess Maxima Center for Pediatric Oncology

Phase 3

1 7

Furmonertinib

AAllist Pharmaceuticals, Inc.

Phase 2

2 8

AK112

SSummit Therapeutics

Phase 2

1 9

Tagrisso

AstraZeneca

Preclinical

1 10

Rybrevant

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 1Not yet recruiting

Leptomeningeal Metastases

NCT07674693

Q4 2031

PreclinicalRecruiting

Leptomeningeal Metastasis

NCT07098806

Clinical

Trials by Indication[1]

Leptomeningeal Metastasis2 trials

A Multicenter Phase 1 Clinical Study to Determine the Maximum Tolerated Dose/Maximum Feasible Dose, Safety,& Efficacy of Single Dose Rhenium-186 NanoLiposome (186RNL) Administered Via Intraventricular Catheter for Leptomeningeal Metastases

Completed·PPlus Therapeutics·Phase 1·NCT05034497·37 enrolled

A Multicenter Phase 1 Study to Determine the Safety and Efficacy of Multiple Doses at Defined Intervals of Rhenium (186Re) Obisbemeda (Rhenium-186 NanoLiposome, 186RNL) Administered Via Intraventricular Catheter for Any Primary Solid Tumor Cancer With Leptomeningeal Metastases

Recruiting·PPlus Therapeutics·Preclinical·NCT07098806·24 enrolled

Leptomeningeal Metastases1 trial

A Phase 1 Study to Determine the Safety and Tolerability of Whole Brain Radiotherapy (WBRT) or Proton Craniospinal Irradiation (PCSI) With Multiple Doses of Rhenium-186 NanoLiposome (186RNL, REYOBIQ) Administered Via Intraventricular Catheter for Leptomeningeal Metastases

Not yet recruiting·NNYU Langone Health·Phase 1·NCT07674693·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for 186rnl. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 186rnl. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — NYU Langone Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: NNYU Langone Health

186rnl

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2031

Q4 2031

Trials by Indication[1]

Leptomeningeal Metastasis2 trials

Leptomeningeal Metastases1 trial

References

Drug Info

Quick Facts

Related News